In a first-of-its-kind study, a stem cell therapy consisting of human placenta-derived stromal cells was shown to be safe in multiple sclerosis (MS) patients. The Phase 1b study of this cellular therapy, called PDA-001, was led by researchers from The Mount Sinai Hospital in New York jointly with Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation. This approach could provide a new avenue for MS therapy development, as these cells are more abundant than bone marrow-derived mesenchymal stem cells, and a single donor can supply sufficient cells for many patients. Although the study was geared toward safety testing, preliminary assessment suggests that PDA-001 may lead to repair of damaged tissue in this disease.
Click here for more details about this groundbreaking study.Share this: